2022
Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence
Miller C, Althoff K, Schlueter D, Anton-Culver H, Chen Q, Garbett S, Ratsimbazafy F, Thomsen I, Karlson E, Cicek M, Pinto L, Malin B, Ohno-Machado L, Williams C, Goldstein D, Kouame A, Ramirez A, Gebo K, Schully S. Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence. MSphere 2022, 7: e00257-22. PMID: 36173112, PMCID: PMC9599436, DOI: 10.1128/msphere.00257-22.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 antibody concentrationsLow prevalenceVaccine availabilitySARS-CoV-2 enzyme-linked immunosorbent assayFalse positivityLow SARS-CoV-2 prevalenceSARS-CoV-2 IgG assaysSARS-CoV-2 IgG testSARS-CoV-2 IgG antibodiesSevere acute respiratory syndrome coronavirus 2Coronavirus disease 2019 prevalenceAcute respiratory syndrome coronavirus 2Antibody concentrationsSARS-CoV-2 testDifferent antigensRespiratory syndrome coronavirus 2SARS-CoV-2 prevalenceSyndrome coronavirus 2SARS-CoV-2 pandemicConcordant positive resultsConcordant negative resultsEnzyme-linked immunosorbent assayPositive resultsFuture pandemic preparednessConcordance of results
2021
Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020
Althoff K, Schlueter D, Anton-Culver H, Cherry J, Denny J, Thomsen I, Karlson E, Havers F, Cicek M, Thibodeau S, Pinto L, Lowy D, Malin B, Ohno-Machado L, Williams C, Goldstein D, Kouame A, Ramirez A, Roman A, Sharpless N, Gebo K, Schully S. Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in All of Us Research Program Participants, 2 January to 18 March 2020. Clinical Infectious Diseases 2021, 74: 584-590. PMID: 34128970, PMCID: PMC8384413, DOI: 10.1093/cid/ciab519.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayBlood specimensSARS-CoV-2 enzyme-linked immunosorbent assaySARS-CoV-2 immunoglobulin G (IgG) antibodiesSARS-CoV-2 antibodiesIgG enzyme-linked immunosorbent assayConfidence intervalsImmunoglobulin G antibodiesSARS-CoV-2Sequential testing algorithmEUROIMMUN assaysSymptomatic patientsTesting algorithmStudy visitG antibodiesCommunity transmissionTravel historyStudy participantsUS epidemicEarly weeksImmunosorbent assayTesting capacityAntibodiesWeeksUS states